home / stock / alim / alim news

ALIM News and Press, Alimera Sciences Inc. From 02/24/22

Stock Information
Company Name: Alimera Sciences Inc.
Stock Symbol: ALIM
Market: NASDAQ
Website: alimerasciences.com
Menu
ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board
Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...
ALIM - Alimera Sciences Reports Fourth Quarter and FY 2021 Results

Fourth Quarter Highlights: Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of 2021; Up 1% vs. Fourth Quarter of 2020 Full Year 2021 Highlights: Consolidated Net Revenue of $59 Million Up 16% vs 2020 Consolidated Net ...
ALIM - Alimera Sciences Q4 2021 Earnings Preview

Alimera Sciences (NASDAQ:ALIM) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.28 and the consensus Revenue Estimate is $13.4M (-2.7% Y/Y). For further details see: Alimera Sciences Q4 2021 Earnings Preview ...

ALIM - Alimera's 3-year data for ILUVIEN shows benefit in diabetic macular edema

Alimera Sciences (NASDAQ:ALIM) reported three-year results of a study called PALADIN evaluating the ILUVIEN implant in patients with diabetic macular edema (DME), an eye complication in people with diabetes. The results, which were published in the journal Ophthalmology, showed...

ALIM - Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology

Best corrected visual acuity and central subfield thickness were significantly improved at 36 months ILUVIEN treatment resulted in a 70.5% reduction in treatment burden Results confirm that use of prior corticosteroid per the U.S. label mitigates the ri...
ALIM - Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

ATLANTA, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with ...

ALIM - Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain

ATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...

ALIM - Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference

ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announ...
ALIM - 36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8 th - 11 th , 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The vir...

ALIM - Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences

ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with ...

ALIM - Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors

ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announ...
Previous 10 Next 10